TransMedics Group (NASDAQ:TMDX) Trading Down 9.5% - Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s stock price dropped 9.5% during mid-day trading on Monday . The stock traded as low as $62.24 and last traded at $62.26. Approximately 622,869 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 3,603,287 shares. The stock had previously closed at $68.81.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMDX shares. Canaccord Genuity Group lowered their price target on TransMedics Group from $109.00 to $104.00 and set a "buy" rating on the stock in a research report on Wednesday, November 20th. TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a "buy" rating on the stock in a report on Monday, November 18th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Oppenheimer reiterated an "outperform" rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Piper Sandler lowered their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $122.70.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market cap of $2.03 billion, a PE ratio of 64.30 and a beta of 2.12. The business has a 50 day moving average price of $72.63 and a two-hundred day moving average price of $119.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.12) earnings per share. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This trade represents a 90.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by company insiders.

Institutional Trading of TransMedics Group

Large investors have recently added to or reduced their stakes in the stock. Amalgamated Bank lifted its position in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company's stock worth $168,000 after purchasing an additional 70 shares during the period. Harbour Capital Advisors LLC lifted its holdings in TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company's stock worth $760,000 after buying an additional 81 shares during the period. Venturi Wealth Management LLC lifted its holdings in TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company's stock worth $136,000 after buying an additional 219 shares during the period. National Bank of Canada FI boosted its position in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Finally, Quarry LP grew its holdings in shares of TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company's stock worth $58,000 after acquiring an additional 312 shares during the period. Institutional investors own 99.67% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.